Retigabine IR

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Epilepsy

Phase 3

Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures

CompletedNCT01227902

GlaxoSmithKlineEpilepsy

Start: 2010-07-31End: 2012-12-31Updated: 2014-10-17

Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)

CompletedNCT01336621

GlaxoSmithKlineEpilepsy

Start: 2011-02-21End: 2017-09-13Updated: 2020-03-11

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

CompletedNCT01777139

GlaxoSmithKlineEpilepsy

Start: 2013-04-11End: 2017-09-13Updated: 2020-03-11

Related Papers

Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events.

2019-11-1233 citations

Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.

2015-06-089 citations